NeuroMetrix Initiates Patient-Focused Program for Early Detection of Diabetic Peripheral Neuropathy by Podiatrists Business Wire WALTHAM, Mass. -- April 1, 2014 NeuroMetrix, Inc. (the “Company”) (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that helps patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances, today announced an initiative to improve the detection and awareness of diabetic peripheral neuropathy, or DPN, at a reasonable cost to patients. The program is targeted at podiatric physicians and offers creative commercial terms to incorporate a DPN screening program into their clinical practice with NC-stat^® DPNCheck^® technology. This objective test will allow them to more accurately assess their patients with diabetes for DPN and enhance the podiatric care they provide. NC-stat DPNCheck addresses an unmet medical need for accurate and cost-effective screening, diagnosing and monitoring of DPN. This complication of diabetes affects over 50% of diabetics and leads to foot ulcers and limb amputation, as well as severe pain and an overall reduction in patient quality of life. NC-stat DPNCheck has found growing acceptance among larger Medicare Advantage plans where the test is used in the clinically and financially important risk adjustment process. U.S. podiatrists number approximately 15,000. Their central role in managing DPN and its complications positions them to advise patients on the benefits of early DPN detection in guiding treatment. Recent studies have not only confirmed the benefits to patients of podiatric care but also the significant savings in health care costs due to lower risks of hospitalization and amputation where podiatrists are involved in the care of patients with diabetes. Screening with NC-stat DPNCheck will help podiatrists identify patients likely to benefit from intensive podiatric care. “NC-stat DPNCheck is well suited to the podiatrist with a significant diabetes practice,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “Patients will benefit from awareness and treatment that more accurately takes into account their condition. Podiatrists will find that DPN screening can be efficiently adopted in their medical practice to improve patient risk assessment while contributing to practice economics.” About NeuroMetrix NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances. The Company has a major focus on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy and other forms of chronic pain such as fibromyalgia, post herpetic neuropathy (shingles), and conditions with both chronic pain and disturbed sleep such as restless leg syndrome. The company also markets the DPNCheck^® device, which is a rapid, accurate, and quantitative point-of-care test for peripheral neuropathies such as diabetic neuropathy. This product is used to detect neuropathies at an early stage and to guide treatment. For more information, please visit http://www.NeuroMetrix.com. Contact: NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief Financial Officer firstname.lastname@example.org
NeuroMetrix Initiates Patient-Focused Program for Early Detection of Diabetic Peripheral Neuropathy by Podiatrists
Press spacebar to pause and continue. Press esc to stop.